Autres langues Avidity Biosciences, Inc.

Actions

RNA

US05370A1088

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
26,45 ^USD	+3,40%		+8,58%	+192,27%

04/04	Un initié d'Avidity Biosciences a vendu des actions pour une valeur de 734 919 $, selon un récent dépôt auprès de la SEC	MT
04/04	Un initié d'Avidity Biosciences a vendu des actions pour une valeur de 542 214 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Avidity Biosciences : April 2024 Corporate Presentation	30/04
Avidity Biosciences : (5.7 MB)	29/04
Avidity Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	23/04
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22/04
Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	04/04
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	04/04
Avidity Biosciences to Participate in Upcoming Investor Conferences	27/03
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	21/03
Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding	19/03
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing	15/03
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing	13/03
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing	05/03
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial	04/03
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Avidity Biosciences Honors Rare Disease Day	01/03
Avidity Biosciences Honors Rare Disease Day®	29/02
Apprehension About Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday	29/02
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement	29/02
Avidity Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Avidity Biosciences, Inc.

Actions

RNA

US05370A1088

Autres langues

Filtres